Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of glofitamab + Pola-R-CHP versus Pola-R-CHP in previously untreated large B-cell lymphoma
CTR20232656Phase 3Active
- Sponsor
- Roche
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of glofitamab, polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Started Dec 2023; status: active.
02
Drugs
glofitamabpolatuzumab vedotinrituximabcyclophosphamidedoxorubicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20232656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232656.